博碩士論文 101224013 詳細資訊




以作者查詢圖書館館藏 以作者查詢臺灣博碩士 以作者查詢全國書目 勘誤回報 、線上人數:5 、訪客IP:35.172.233.215
姓名 李太榮(Tai-rong Lee)  查詢紙本館藏   畢業系所 生命科學系
論文名稱 利用聚乙烯亞胺輸送環狀核苷酸磷酸二酯酶4B之專一性反義寡核苷酸可抑制LPS刺激小鼠巨噬細胞釋放TNF-α
(Delivery of antisense oligonucleotides specific to phosphodiesterase 4B gene by polyethylenimine downregulates LPS-induced TNF-α release in mouse macrophages)
相關論文
★ PDE抑制劑與cAMP訊號傳導對類風濕性關節炎小鼠模型中CD4+ T細胞釋放IFN-g與IL-17A之調控★ PDE4和cAMP訊號傳導於小鼠骨髓細胞分化為樹突細胞之角色
★ 利用斑馬魚研究肝臟疾病和肝癌之發生:B型肝炎病毒X抗原,黃麴毒素,p53突變,src和edn1的致癌作用及其協同效應★ 環狀核苷酸磷酸二酯酶4對LPS/TLR4訊息傳導誘導小鼠巨噬細胞表現IFN-β的影響
★ 抑制環狀核苷酸磷酸二酯酶 3 (PDE3)對 3T3-L1 脂肪細胞內蛋白質表現之影響★ 環狀核苷酸磷酸二酯酶4B對小鼠樹突細胞分化與CXCR4表現之調控
★ PDE4與PDE3抑制劑對膠原蛋白誘發DBA/1小鼠關節炎及釋放發炎激素IFN-γ與IL-17A的協同調控作用★ 環狀核苷酸磷酸二酯酶4B對內毒素誘導巨噬細胞 產生IL-1Ra和樹突細胞表現TLRs之影響 及其對乾癬症生成之潛在角色
★ 環狀核苷酸磷酸二脂酶4B對內毒素刺激小鼠樹突細胞表現NOD1與CXCR4的影響★ Viscolin對不同免疫細胞發炎反應的影響
★ 環狀腺苷單磷酸與其它訊息傳遞因子對脂肪細胞釋放阻抗素之影響★ 環狀核苷酸磷酸二酯酶4B對於小鼠T細胞功能之調節
★ 巨噬細胞中抑制PDE4對LPS誘導發炎反應之調控★ 環狀核苷酸磷酸二酯酶4對LPS刺激小鼠巨噬細胞產生IL-1Ra之影響
★ 調控小鼠脂肪細胞釋放阻抗素之訊息傳導路徑★ 環狀核苷磷酸二酯酶4對LPS刺激小鼠巨噬細胞產生IP-10之影響
檔案 [Endnote RIS 格式]    [Bibtex 格式]    [相關文章]   [文章引用]   [完整記錄]   [館藏目錄]   至系統瀏覽論文 ( 永不開放)
摘要(中) PDE4B在免疫細胞內會參與多種免疫發炎反應,且與許多發炎疾病息息相關,因此若能有效調控PDE4B mRNA表現及PDE4B酵素生成應可有效減緩該等發炎反應之相關病症。已知PDE4抑制劑roflumilast與apremilast為有效的抗發炎藥劑,但在臨床上會產生副作用如噁心、腸炎等使療效受限,而研究顯示該等副作用主要是由於PDE4抑制劑缺乏PDE4B選擇性所致,因此,研發PDE4B專一性藥劑將有助於發炎疾病的治療。有鑑於此,本研究擬以PDE4B專一性反義寡核苷酸(Antisense oligonucleotide, ASO)藉由反義寡核苷酸運輸策略(antisense approach)達到此目的。已知DNA分子本身無法有效穿越細胞膜進入細胞內,因此需藉由不同的載體輸送,如脂質體(liposome)、穿膜胜肽(Cell-penetrating peptide)或正電荷聚合物(cationic polymer)等。本研究主要是利用正電荷聚合物-聚乙烯亞胺(Polyethylenimine, PEI)為載體以檢測其是否可有效輸送ASO到免疫細胞內調控免疫發炎反應。我們將PEI分別與不同的TNF-α和PDE4B ASO形成複合物,並轉染至Raw 264.7巨噬細胞以評估其調控LPS誘導TNF-α產生的功效。結果顯示,以不同的PEI與ASO電荷比(N/P ratio)進行實驗,只有N/P為100時會抑制TNF-α的釋放,而在四個TNF ASO (TNF1 ~ 4 ASO)中,僅PEI/TNF3 ASO複合物有顯著抑制作用,且其抑制程度(約30%)與控制組TNF5 ASO (約33%)相當。再者,將PEI與四個PDE4B ASO (PDE4B-1 ~ 4 ASO)形成複合物進行實驗,我們發現PDE4B-2、PDE4B-3與PDE4B-4 ASO均可顯著抑制LPS誘導TNF-α的釋放且無明顯的細胞毒性,其中又以PDE4B-4 ASO效果最佳(抑制約58%)。此外,PDE4B-3與PDE4B-4 ASO之抑制程度均較TNF ASO直接抑制TNF-α mRNA為佳。由這些結果推測,PDE4B ASO是經由抑制細胞內PDE4B mRNA,進而降低PDE4B酵素生成,使cAMP濃度上升並活化PKA,再間接抑制LPS誘導TNF-α的產生。我們進一步以動態雷射散射粒徑分析儀檢測PEI/ASO複合物的特性,結果顯示,於N/P電荷比為100時,其表面電位介於30 ~ 45 mV,且粒徑大小約為400 nm ~ 600 nm,此符合胞吞作用進行的條件。綜合以上結果,我們認為PEI/PDE4B-4 ASO於N/P電荷比為100時,會有效進入巨噬細胞內並抑制發炎反應,且又無明顯的細胞毒性,因此以PEI輸送PDE4B-4 ASO極具潛力應用於基因治療上。
摘要(英) Phosphodiesterase 4B (PDE4B) is essential for various immune and inflammatory responses and hence plays important role in the pathogenesis of several inflammatory diseases. The nonselective PDE4 inhibitors, including the clinically approved roflumilast and apremilast, have been shown to effectively ameliorate inflammatory diseases, but the side effects such as emesis and enteritis have limited their dosing and thereby the immunomodulatory effects. Therefore, development of inhibitors selective for PDE4B is considered a promising approach to improve the therapeutic windows. To this purpose, different PDE4B-specific antisense oligonucleotides (PDE4B ASO) were designed in this study and the cationic polymer polyethylenimine (PEI) was employed as a carrier to deliver the ASO into Raw 264.7 macrophages to test their effect on lipopolysaccharide (LPS)-stimulated TNF-α production. The TNFα-specific ASOs were also designed for comparison. The results showed that at the ASO concentration of 0.2 uM and N/P charge ratio of 100, several ASO tested significantly suppressed LPS-induced TNF-α release without cytotoxicity. Among the four TNF-α ASO (TNF1~4 ASO) tested, only TNF3 ASO produced inhibitory effect on TNF-α release, and its level of inhibition was similar to that of the control TNF5 ASO. As for the four PDE4B ASO (PDE4B-1~4 ASO), three (PDE4B-2, 3, and 4) were shown to significantly inhibit the LPS-induced TNF-α release, and among which the PDE4B-4 ASO displayed the highest inhibition (approximately 58%). Moreover, the PEI/PDE4B-3 and PEI/PDE4B-4 complexes were more effective in blocking the TNF-α release compared to all PEI/TNF-α ASO tested. The analysis of PEI/ASO complexes by dynamic laser scattering (DLS) revealed that at the N/P ratio of 100 all of the complexes had the surface charge of 30-45 mV and the size of 400-600 nm, which is known to be appropriate for endocytosis of nanoparticles. Collectively, the results indicated that the PEI/PDE4B-4 ASO complex at the ASO concentration of 0.2 uM and N/P ration of 100 may reproduce the anti-inflammatory effects of nonselective PDE4 inhibitors but devoid of their side effects. Therefore, it has the potential for therapeutic application in inflammatory diseases.
關鍵字(中) ★ 環狀核苷酸磷酸二酯酶4B
★ 聚乙烯亞胺
★ 反義寡核苷酸
★ 腫瘤壞死因子
關鍵字(英)
論文目次 中文摘要 i
英文摘要 iii
誌謝 v
目錄 vi
圖目錄 ix
表目錄 x
縮寫檢索表 xi
一、緒論 1
1-1基因治療(Gene therapy) 1
1-2基因傳輸系統(Gene delivery system) 2
1-2-1病毒型載體(viral vector) 2
1-2-2非病毒型載體(non-viral vector) 2
1-3正電荷聚合物(Cationic polymers)與基因治療 3
1-4胜肽(Peptide)與基因治療 5
1-5反義寡核苷酸(Antisense oligonucleotide, ASO)之結構修飾 6
1-6腫瘤壞死因子(Tumor necrosis factor α)與免疫反應 8
1-7環狀核苷酸磷酸二酯酶(Cyclic nucleotide phosphodiesterase, PDE 9
1-7-1 PDE4家族 11
1-7-2 PDE4對巨噬細胞發炎反應之影響 11
1-8陽離子脂質體(Cationic liposome)與基因治療 12
二、研究動機與目的 14
三、材料與方法 15
3-1材料 15
3-1-1細胞株 15
3-1-2細胞培養液 15
3-1-3反義寡核苷酸(Antisense oligonucleotide, ASO) 15
3-1-4 R9胜肽(9-Arginine peptide) 16
3-1-5化學藥品 16
3-1-6實驗試劑配製 16
3-2實驗方法 17
3-2-1 Raw 264.7巨噬細胞培養 17
3-2-2 Raw 264.7巨噬細胞轉染(Transfection) 17
3-2-3配製不同N/P電荷比例(N/P ratio)之PEI/ASO複合物 17
3-2-4 Raw 264.7巨噬細胞的藥物處理 18
3-2-5 MTT試驗(MTT assay)檢測細胞存活率 19
3-2-6 TNF-α含量測定 19
3-2-7雷射粒徑分佈(dynamic light scattering, DLS)分析 19
3-2-8包覆率分析 20
四、實驗結果 21
4-1利用lipofectamine輸送TNF ASO以檢測ASO對於TNF-α表現之影響 21
4-2 Lipofectamine/PDE4B ASO複合物對於LPS刺激Raw 264.7細胞釋放TNF-α之影響 22
4-3 PEI/ASO複合物之N/P電荷比與ASO濃度對於LPS刺激Raw 264.7細胞釋放TNF-α之影響 23
4-4 PEI/TNF ASO複合物對於LPS刺激Raw 264.7細胞釋放TNF-α之影響 24
4-5 PEI/PDE4B ASO複合物對於LPS刺激Raw 264.7細胞釋放TNF-α之影響 25
4-6 (Arg)9/PDE4B-4 ASO複合物於不同N/P電荷比對LPS刺激Raw 264.7細胞釋放TNF-α之影響 26
4-7 PEI於不同N/P電荷比對TNF3、PDE4B-4 ASO之包覆能力 26
4-8 PEI/ASO複合物之粒徑大小與表面電荷 27
五、討論 28
六、圖與圖解 32
七、表 41
參考文獻 42
附圖 55
參考文獻 Astriab-Fisher, Anna, Dimitri S. Sergueev, Michael Fisher, Barbara Ramsay Shaw, and Rudolph L. Juliano. 2000. ′Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates′, Biochemical Pharmacology, 60: 83-90.

Baker, A, M Saltik, H Lehrmann, I Killisch, V Mautner, G Lamm, G Christofori, and M Cotten. 1997. ′Polyethylenimine (PEI) is a simple, inexpensive and effective reagent for condensing and linking plasmid DNA to adenovirus for gene delivery′, Gene Therapy, 4: 773–82.

Baker, Brenda F., Sidney S. Lot, Thomas P. Condon, Shin Cheng-Flournoy, Elena A. Lesnik, Henri M. Sasmor, and C. Frank Bennett. 1997. ′2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells′, The Journal of Biological Chemistry, 272: 11994-2000.

Baud, Véronique, and Michael Karin. 2001. ′Signal transduction by tumor necrosis factor and its relatives′, Trends Cell Biology, 11: 372-7.

Benimetskaya, Lyuba, John D. Loike, Zahangir Khaled, Gila Loike, Samuel C. Silverstein, Long Cao, Joseph El Khoury, Tian-Quan Cai, and C. A. Stein. 1997. ′Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein′, Nature Medicine, 3: 414-20.

Blessing, Thomas, Malgorzata Kursa, Robert Holzhauser, Ralf Kircheis, and Ernst Wagner. 2001. ′Different Strategies for Formation of PEGylated EGF-Conjugated PEI/DNA Complexes for Targeted Gene Delivery′, Bioconjugate Chemistry, 12: 529-37.

Boussif, Otmane, Frank Lezoualc′h, Marla Antonietra Zanta, Mojgan Djavaheri Mergny, Daniel Scherman, Barbara Demeneix, and Jean-Paul Behr. 1995. ′A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine′, Proceedings of the National Academy of Sciences of the United States of America, 92: 7297-301.

Brown, David A., Shin-Heh Kang, Sergei M. Gryaznov, Larry DeDionisio, Olaf Heidenreich, Sean Sullivan, Xiao Xu, and Michael I. Nerenberg. 1994. ′Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding′, The Journal of Biological Chemistry, 269: 26801-5.

Brynskov, J, P Foegh, G Pedersen, C Ellervik, T Kirkegaard, A Bingham, and T Saermark. 2002. ′Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease′, Gut, 51: 37-43.

Bunnell, Bruce A., and Richard A. Morgan. 1998. ′Gene Therapy for Infectious Diseases′, Clinical Microbiology Reviews, 11: 42–56.

Campeau, P, P Chapdelaine, S Seigneurin-Venin, B Massie, and JP Tremblay. 2001. ′Transfection of large plasmids in primary human myoblasts′, Gene Therapy, 8: 1387-94.

Carswell, E. A., L. J. Old, R. L. Kassel, S. Green, N. Fiore, and B. Williamson. 1975. ′An endotoxin-induced serum factor that causes necrosis of tumors′, Proceedings of the National Academy of Sciences of the United States of America, 72: 3666-70.

Chung, Kian Fan. 2006. ′Phosphodiesterase inhibitors in airways disease′, European Journal of Pharmacology, 533: 110-7.

Conti, Marco, and Joseph Beavo. 2007. ′Biochemistry and Physiology of Cyclic Nucleotide Phosphodiesterases: Essential Components in Cyclic Nucleotide Signaling′, Annual Review of Biochemistry, 76: 481-511.

Crooke, Stanley T. 2000. ′Progress in antisense technology: the end of the beginning′, Methods In Enzymology, 313: 3-45.

Crooke, Stanley T., Kristina M. Lemonidis, Lorna Neilson, Richard Griffey, Elena A. Lesnik, and Brett P. Monia. 1995. ′Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes′, Biochemical Journal, 312: 599-608.
Cui, Shaohui, Shubiao Zhang, Huiying Chen, Bing Wang, Yinan Zhao, and Defu Zhi. 2012. ′The Mechanism of Lipofectamine 2000 Mediated Transmembrane Gene Delivery′, Engineering, 04: 172-75.

D.Houslay, Miles, Peter Schafer, and Kam Y.J.Zhang. 2005. ′Keynote review: Phosphodiesterase-4 as a therapeutic target′, Drug Discovery Today, 10: 1503-19.

Dalby, Brian, Sharon Cates, Adam Harris, Elise C. Ohki, Mary L. Tilkins, Paul J. Price, and Valentina C. Ciccarone. 2004. ′Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications′, Methods, 33: 95-103.

Dathe, Margitta, Michael Schu¨mann, Torsten Wieprecht, Anett Winkler, Michael Beyermann, Eberhard Krause, Katsumi Matsuzaki, Osamu Murase, and Michael Bienert. 1996. ′Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes′, Biochemistry, 35: 12612-22.

Derossi, Daniele, Main H. Joliot, G6rard Chassaing, and Main Prochiantz. 1994. ′The third helix of the Antennapedia homeodomain translocates through biological membranes′, The Journal of Biological Chemistry, 269: 10444-50.

Deventer, S J Van. 1997. ′Tumour necrosis factor and Crohn′s disease′, Gut, 40: 443–8.

Dishart, Kate L., Lorraine M. Work, Laura Denby, and Andrew H. Baker. 2003. ′Gene Therapy for Cardiovascular Disease′, Journal of Biomedicine and Biotechnology, 2003: 138–48.

Dong, Lei, Zhen Huang, Xing Cai, Jiawei Xiang, Yi-An Zhu, Rui Wang, Jiangning Chen, and Junfeng Zhang. 2010. ′Localized Delivery of Antisense Oligonucleotides by Cationic Hydrogel Suppresses TNF-α Expression and Endotoxin-Induced Osteolysis′, Pharmaceutical Research, 28: 1349-56.

Dong, Lei, Suhua Xia, Yi Luo, Huajia Diao, Jiani Zhang, Jiangning Chen, and Junfeng Zhang. 2009. ′Targeting delivery oligonucleotide into macrophages by cationic polysaccharide from Bletilla striata successfully inhibited the expression of TNF-alpha′, Journal of Controlled Release, 134: 214-20.

Ferreira, Guilherme N.M., Gabriel A. Monteiro, Duarte M.F. Prazeres, and Joaquim M.S. Cabral. 2000 ′Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications′, Trends Biotechnology, 18: 380-8.

Fischer, Dagmar, Thorsten Bieber, Youxin Li, Hans-Peter Elsässer, and Thomas Kissel. 1999. ′A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity′, Pharmaceutical Research, 16: 1273-9.

Futaki, Shiroh, Wakana Ohashi, Tomoki Suzuki, Miki Niwa, Seigo Tanaka, Kunihiro Ueda, Hideyoshi Harashima, and Yukio Sugiura. 2001. ′Stearylated arginine-rich peptides: a new class of transfection systems′, Bioconjugate Chemistry, 12: 1005-11.

Futaki, Shiroh, Tomoki Suzuki, Wakana Ohashi, Takeshi Yagami, Seigo Tanaka, Kunihiro Ueda, and Yukio Sugiura. 2001. ′Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery′, The Journal of Biological Chemistry, 276: 5836-40.

Gao, Jian-Qing, Qing-Qing Zhao, Teng-Fei Lv, Wu-Ping Shuai, Jun Zhou, Gu-Ping Tang, Wen-Quan Liang, Yasuhiko Tabata, and Yu-Lan Hu. 2010. ′Gene-carried chitosan-linked-PEI induced high gene transfection efficiency with low toxicity and significant tumor-suppressive activity′, International Journal of Pharmaceutics, 387: 286-94.

Gao, Lizeng, Leng Nie, Taihong Wang, Yujun Qin, Zhixin Guo, Dongling Yang, and Xiyun Yan. 2006. ′Carbon nanotube delivery of the GFP gene into mammalian cells′, Chembiochem, 7: 239-42.

Gao, Xiang, Keun-Sik Kim, and Dexi Liu. 2007. ′Nonviral Gene Delivery: What We Know and What Is Next′, The AAPS Journal, 9: 92-104.

Gardlík, Roman, Roland Pálffy, Július Hodosy, Ján Lukács5, Ján Turňa, and Peter Celec. 2005. ′Vectors and delivery systems in gene therapy′, Medical Science Monitor, 11: 110-21.
Godbey, W. T., Kenneth K. Wu, and Antonios G. Mikos. 1999. ′Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle′, Journal of Biomedical Materials Research, 45: 268-75.

Guvakova, Marina A., Leonid A. Yakubov, Israel Vlodavsky, John L. Tonkinson, and C. A. Stein. 1995. ′Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix′, The Journal of Biological Chemistry, 270: 2620-7.

Henry, Scott P., Patricia C. Giclas, Janet Leeds, Michael Pangburn, Carol Auletta, Arthur A. Levin, and Douglas J. Kornbrust. 1997. ′Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action′, Journal of Pharmacology and Experimental Therapeutics, 281: 810-6.

Huang, Zhen, Zhengping Zhang, Yinhe Zha, Jialin Liu, Yucui Jiang, Yang Yang, Juan Shao, Xulun Sun, Xin Cai, Yuan Yin, Jiangning Chen, Lei Dong, and Junfeng Zhang. 2012. ′The effect of targeted delivery of anti-TNF-α oligonucleotide into CD169+ macrophages on disease progression in lupus-prone MRL/lpr mice′, Biomaterials, 33: 7605-12.

Ibraheem, D., A. Elaissari, and H. Fessi. 2014. ′Gene therapy and DNA delivery systems′, International Journal of Pharmaceutics, 459: 70-83.

Inoue, Takayoshi, and Robb Krumlauf. 2001. ′An impulse to the brain - using in vivo electroporation′, nature neuroscience supplement, 4: 1156-8.

Jakobsen, Maria, Karin Stenderup, Cecilia Rosada, Brian Moldt, Søren Kamp, Tomas N. Dam, Thomas G. Jensen, and Jacob Giehm Mikkelsen. 2009. ′Amelioration of Psoriasis by Anti-TNF-α RNAi in the Xenograft Transplantation Model′, Molecular Therapy, 17: 1743-53.

Jansen, B, V Wacheck, E Heere-Ress, H Schlagbauer-Wadl, C Hoeller, T Lucas, M Hoermann, U Hollenstein, K Wolff, and H Pehamberger. 2000. ′Chemosensitisation of malignant melanoma by BCL2 antisense therapy′, The Lancet, 356: 1728-33.

Jin, S.-L., and Marco Conti. 2002. ′Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses′, Proceedings of the National Academy of Sciences of the United States of America, 99: 7628-33.

Jin, S.-L., Shiau-Li Ding, and Shih-Chang Lin. 2012. ′Phosphodiesterase 4 and its inhibitors in inflammatory diseases′, Chang Gung Medical Journal, 35: 197-210.

Jin, S.-L., Sho Goya, Susumu Nakae, Dan Wang, Matthew Bruss, Chiaoyin Hou, Dale Umetsu, and Marco Conti. 2010. ′Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma′, Journal of Allergy and Clinical Immunology, 126: 1252-9 e12.

Jin, S.-L., Linda Lan, Maria Zoudilova, and Marco Conti. 2005. ′Specific Role of Phosphodiesterase 4B in Lipopolysaccharide-Induced Signaling in Mouse Macrophages′, The Journal of Immunology, 175: 1523-31.

Kang, Seung Hee, Hee-Jeong Cho, Gayong Shim, Sangbin Lee, Su-Hyeon Kim, Han-Gon Choi, Chan-Wha Kim, Yu-Kyoung, and Seunguk Oh. 2011. ′Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy′, Pharmaceutical Research, 28: 3069-78.

Kaufmann, Kerstin B., Hildegard Bu¨ning, Anne Galy, Axel Schambach, and Manuel Grez. 2013. ′Gene therapy on the move′, EMBO Molecular Medicine, 5: 1642-61.

Kilk, Kalle, Samir EL-Andaloussi, Peter J7rver, Anne Meikas, Andres Valkna, Tamas Bartfai, Priit Kogerman, Madis Metsis, and U¨ lo Langel. 2005. ′Evaluation of transportan 10 in PEI mediated plasmid delivery assay′, Journal of Controlled Release, 103: 511-23.

Kircheis, Ralf, Lionel Wightman, and Ernst Wagner. 2001. ′Design and gene delivery activity of modified polyethylenimines′, Advanced Drug Delivery Reviews, 53: 341-58.

Knipe, Jennifer M., Jonathan T. Peters, and Nicholas A. Peppas. 2013. ′Theranostic agents for intracellular gene delivery with spatiotemporal imaging′, Nano Today, 8: 21-38.

Kurreck, Jens. 2003. ′Antisense technologies. Improvement through novel chemical modifications′, European Journal of Biochemistry, 270: 1628-44.

Kurreck, Jens, Eliza Wyszko, Clemens Gillen, and Volker A. Erdmann. 2002. ′Design of antisense oligonucleotides stabilized by locked nucleic acids′, Nucleic Acids Research, 30: 1911-8.

Lai, Ciou-Rong, Huan-Chu Lo, Yi-Ling Chen, Jing-Xing Yang, Shiau-Li Ding, Hsian-He Hsu, Marco Conti, Chin-Pyng Wu, and S.-L. Jin. 2015. ′Phosphodiesterase 4b is essential for lipopolysaccharide-induced CC chemokine ligand 3 production in mouse macrophages′, Journal of Medical Sciences, 35: 111.

Lehrman, Sally. 1999. ′Virus treatment questioned after gene therapy death′, Nature, 401: 517-18.

Levin, Arthur A. 1999. ′A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides′, Biochimica et Biophysica Acta, 148: 69-84.

Liu, Ge, Maria Molas, Gregory A. Grossmann, Murali Pasumarthy, Jose C. Perales, Mark J. Cooper, and Richard W. Hanson. 2001. ′Biological properties of poly-L-lysine-DNA complexes generated by cooperative binding of the polycation′, The Journal of Biological Chemistry, 276: 34379-87.

Luo, Dan, and W. Mark Saltzman. 2000. ′Synthetic DNA delivery systems′, Nature Biotechnology, 18: 33-7.

Mével, Mathieu, Nazila Kamaly, Sergio Carmona, Morag H. Oliver, Michael R. Jorgensen, Carol Crowther, Felix H. Salazar, Patricia L. Marion, Masato Fujino, and Yukikazu Natori. 2010. ′DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA′, Journal of Controlled Release, 143: 222-32.

Mahato, Ram I, Kun Cheng, and Ramareddy V Guntaka. 2005. ′Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA′, Expert Opinion on Drug Delivery, 2: 3-28.

Marschall, P, N Malik, and Z Larin. 1999. ′Transfer of YACs up to 2.3 Mb intact into human cells with polyethylenimine′, Gene Therapy, 6: 1634-7.

Matsukura, Makoto, Kazuo Shinozuka, Gerald Zon, Hiroaki Mitsuya, Marvin Reitz, Jack S. Cohen, and Samuel Broder. 1987. ′Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus′, Proceedings of the National Academy of Sciences of the United States of America, 84: 7706-10.

Meunier-Durmort, C, H Grimal, LM Sachs, BA Demeneix, and C Forest. 1997. ′Adenovirus enhancement of polyethylenimine-mediated transfer of regulated genes in differentiated cells′, Gene Therapy, 4: 808-14.

Mintzer, Meredith A., and Eric E. Simanek. 2009. ′Nonviral Vectors for Gene Delivery′, Chemical Reviews, 109: 259–302.

Mitchell, D.J., D.T. Kim, L. Steinman, C.G. Fathman, and J.B. Rothbard. 2000. ′Polyarginine enters cells more efficiently than other polycationic homopolymers′, Journal of Peptide Research, 56: 318-25.

Modlich, Ute, Jens Bohne, Manfred Schmidt, Christof von Kalle, Sabine Kno¨ss, Axel Schambach, and Christopher Baum. 2006. ′Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity′, Blood, 108: 2545-53.

Monia, Brett P., Elena A. Lesnik, Carolyn Gonzalez, Walt F. Lima, Danny McGee, Charles J. Guinosso, Andrew M. Kawasaki, P. Dan Cook, and Susan M. Freier. 1993. ′Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression′, The Journal of Biological Chemistry, 268: 14514-22.

Moreira, C., H. Oliveira, L.R. Pires, S. Simo˜ es, M.A. Barbosa, and A.P. Peˆgo. 2009. ′Improving chitosan-mediated gene transfer by the introduction of intracellular buffering moieties into the chitosan backbone′, Acta Biomaterialia, 5: 2995-3006.
Myers, Kathleen J., Sreekant Murthy, Anne Flanigan, Donna R. Witchell, Madeline Butler, Susan Murray, Andrew Siwkowski, Deborah Goodfellow, Karen Madsen, and Brenda Baker. 2003. ′Antisense Oligonucleotide Blockade of Tumor Necrosis Factor-alpha in Two Murine Models of Colitis′, Journal of Pharmacology and Experimental Therapeutics, 304: 411-24.

Nel, Andre E., Lutz Mädler, Darrell Velegol, Tian Xia, Eric M. V. Hoek, Ponisseril Somasundaran, Fred Klaessig, Vince Castranova, and Mike Thompson. 2009. ′Understanding biophysicochemical interactions at the nano-bio interface′, Nature Materials, 8: 543-57.

O′Brien, John A, and Sarah C R Lummis. 2006. ′Biolistic transfection of neuronal cultures using a hand-held gene gun′, Nature Protocols, 1: 977-81.

Obika, Satoshi, Daishu Nanbu, Yoshiyuki Hari, Jun-ichi Andoh, Ken-ichiro Morio, Takefumi Doi, and Takeshi Imanishi. 1998. ′Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2′-O,4′- C-methyleneribonucleosides′, Tetrahedron Letters, 39: 5401-04.

Oh, Seunguk, G. Elizabeth Pluhar, Elizabeth A. Mcneil, Kurt M. Kroeger, Chunyan Liu, Maria G. Castro, Pedro R. Lowenstein, Andrew Freese, and John R. Ohlfest. 2007. ′Efficacy of nonviral gene transfer in the canine brain′, Journal of Neurosurgery, 107: 136-44.

Omori, Kenji, and Jun Kotera. 2007. ′Overview of PDEs and their regulation′, Circulation Research, 100: 309-27.

Radchatawedchakoon, Widchaya, Ramida Watanapokasin, Aungkana Krajarng, and Boon-ek Yingyongnarongkul. 2010. ′Solid phase synthesis of novel asymmetric hydrophilic head cholesterol-based cationic lipids with potential DNA delivery′, Bioorganic & Medicinal Chemistry, 18: 330-42.

Rochlitz, Christoph F. 2001. ′Gene therapy of cancer′, Swiss Medical Weekly, 131: 4-9.

Rockwell, Patricia, William J. O’connor, Karen King, Neil I. Goldstein, L. M. Zhang, and C. A. Stein. 1997. ′Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides′, Proceedings of the National Academy of Sciences of the United States of America, 94: 6523-8.

Ros, Tatiana Da, Giampiero Spalluto, Maurizio Prato, Tula Saison-Behmoaras, Alexandre Boutorine, and Barbara Cacciari. 2005. ′Oligonucleotides and oligonucleotide conjugates: a new approach for cancer treatment′, Current Medicinal Chemistry, 12: 71-88.

Rothbard, Jonathan B., Sarah Garlington, Qun Lin, Thorsten Kirschberg, Erik Kreider, P. Leo Mcgrane, Paul A. Wender, and Paul A. Khavari. 2000. ′Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation′, Nature Medicine, 6: 1253-7.

Scarfi, Sonia, Marco Giovine, Anna Gasparini, Gianluca Damonte, Enrico Millo, Marina Pozzolini, and Umberto Benatti. 1999. ′Modified peptide nucleic acids are internalized in mouse macrophages RAW 264.7 and inhibit inducible nitric oxide synthase′, FEBS Letters, 451: 264-8.

Schaffert, David, and Manfred Ogris. 2013. ′Nucleic acid carrier systems based on polyethylenimine conjugates for the treatment of metastatic tumors′, Current Medicinal Chemistry, 20: 3456-70.

Shalaby, M. Refaat, Bharat B. Aggarwal, Ernst Rinderknecht, Lloyd P. Svedersky, Bryan S. Finkle, and JR Michael A. Palladino. 1985. ′Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors′, The Journal of Immunology, 135: 2069-73.

Shim, Gayong, Su-Eun Han, Yong-Hee Yu, Sangbin Lee, Han Young Lee, Kwangmeyung Kim, Ick Chan Kwon, Tae Gwan Park, Young Bong Kim, Yong Seok Choi, Chan-Wha Kim, and Yu-Kyoung Oh. 2011. ′Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug′, Journal of Controlled Release, 155: 60-66.

Shim, Gayong, Mi-Gyeong Kim, Joo Yeon Park, and Yu-Kyoung Oh. 2013. ′Application of cationic liposomes for delivery of nucleic acids′, Asian Journal of Pharmaceutical Sciences, 8: 72-80.

Smedt, Stefaan C. De, Joseph Demeester, and Wim E. Hennink. 2000. ′Cationic polymer based gene delivery systems′, Pharmaceutical Research, 17: 113-26.

Somia, Nikunj, and Inder M. Verma. 2000. ′Gene therapy - trials and tribulation′, Nature Reviews Genetics, 1: 91-9.

Stein, C. A., J. Bo Hansen, Johnathan Lai, SiJian Wu, Anatoliy Voskresenskiy, Anja Høg, Jesper Worm, Maj Hedtja¨ rn, Naira Souleimanian, Paul Miller, Harris S. Soifer, Daniella Castanotto, Luba Benimetskaya, Henrik Ørum, and Troels Koch. 2010. ′Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents′, Nucleic Acids Research, 38: e3.

Stribley, John M., Khurram S. Rehman, Hairong Niu, and Gregory M. Christman. 2002. ′Gene therapy and reproductive medicine′, Fertility and Sterility, 77: 645–57.

Takechi, Yuki, Haruka Yoshii, Masafumi Tanaka, Toru Kawakami, Saburo Aimoto, and Hiroyuki Saito. 2011. ′Physicochemical mechanism for the enhanced ability of lipid membrane penetration of polyarginine′, Langmuir, 27: 7099-107.

Thomas, M., and A. M. Klibanov. 2003. ′Non-viral gene therapy: polycation-mediated DNA delivery′, Applied Microbiology and Biotechnology, 62: 27-34.

Thomas, Tiffany, and Henry Ginsberg. 2010. ′Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia′, Current Atherosclerosis Reports, 12: 58-65.

Torphy, Theodore J. 1998. ′Phosphodiesterase isozymes: molecular targets for novel antiasthma agents′, American Journal of Respiratory and Critical Care Medicine, 157: 351-70.

Toth, Peter P. 2011. ′Antisense therapy and emerging applications for the management of dyslipidemia′, Journal of Clinical Lipidology, 5: 441-9.

Tu, Guang-chou, Qing-na Cao, Feng Zhou, and Yedy Israel. 1998. ′Tetranucleotide GGGA motif in primary RNA transcripts. Novel target site for antisense design′, The Journal of Biological Chemistry, 273: 25125-31.

Verbeure, Birgit, Eveline Lescrinier, Jing Wang, and Piet Herdewijn. 2001. ′RNase H mediated cleavage of RNA by cyclohexene nucleic acid (CeNA)′, Nucleic Acids Research, 29: 4941-7.

Vicini, Elena, and Marco Conti. 1997. ′Characterization of an intronic promoter of a cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility′, Molecular Endocrinology, 11: 839-50.

Wagner, Ernst, Matt Cotten, Roland Foisner, and Max L. Birnstiel. 1991. ′Transferrin-polycation-DNA complexes: The effect of polycations on the structure of the complex and DNA delivery to cells′, Proceedings of the National Academy of Sciences of the United States of America, 88: 4255-59.

White, Stephen H., and William C. Wimley. 1994. ′Peptides in lipid bilayers: structural and thermodynamic basis for partitioning and folding′, Current Opinion in Structural Biology, 4: 79-86.

Wu, Hongjiang, Walt F. Lima, and Stanley T. Crooke. 1999. ′Properties of cloned and expressed human RNase H1′, The Journal of Biological Chemistry, 274: 28270-8.

Xiong, F., Z. Mi, and N. Gu. 2011. ′Cationic liposomes as gene delivery system: transfection efficiency and new application′, Pharmazie, 66: 158-64.

Yacyshyn, B. R., C. Barish, J. Goff, D. Dalke, M. Gaspari, R. Yu, J. Tami, F. A. Dorr, and K. L. Sewell. 2002. ′Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn′s disease′, Alimentary Pharmacology & Therapeutics, 16: 1761-70.

Zamaratski, Edouard, P.I. Pradeepkumar, and Jyoti Chattopadhyaya. 2001. ′A critical survey of the structure-function of the antisense oligo/RNA heteroduplex as substrate for RNase H′, Journal of Biochemical and Biophysical Methods, 48: 189-208.

Zauner, Wolfgang, Neil A. Farrow, and Adrian M.R. Haines. 2001. ′In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density′, Journal of Controlled Release, 71: 39-51.

Zhao, Qing-Qing, Jin-Liang Chen, Teng-Fei Lv, Cai-Xia He, Gu-Ping Tang, Wen-Quan Liang, Yasuhiko Tabata, and Jian-Qing Gao. 2009. ′N/P ratio significantly influences the transfection efficiency and cytotoxicity of a polyethylenimine/chitosan/DNA complex′, Biological and Pharmaceutical Bulletin, 32: 706-10.

Zhou, Jiaye, James W. Yockman, Sung Wan Kim, and Steven E. Kern. 2007. ′Intracellular kinetics of non-viral gene delivery using polyethylenimine carriers′, Pharmaceutical Research, 24: 1079-87.

Ziegler, André. 2008. ′Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans′, Advanced Drug Delivery Reviews, 60: 580-97.
指導教授 金秀蓮 審核日期 2016-1-28
推文 facebook   plurk   twitter   funp   google   live   udn   HD   myshare   reddit   netvibes   friend   youpush   delicious   baidu   
網路書籤 Google bookmarks   del.icio.us   hemidemi   myshare   

若有論文相關問題,請聯絡國立中央大學圖書館推廣服務組 TEL:(03)422-7151轉57407,或E-mail聯絡  - 隱私權政策聲明